13 unknown. 13 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Unknown 13 |
| Phase 1 | 5 | Unknown 5 |
Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa ALLO-ASC-SHEET, Vehicle Control - Dystrophic Epidermolysis Bullosa | Phase 2 | Unknown | Anterogen Co., Ltd. | 6 | 2023-05-01 | 2024-04-22 |
| Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene PTW-002 10 mg/g gel, Placebo - Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Unknown | Phoenicis Therapeutics | 8 | 2023-04-30 | 2023-03-31 |
| Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa. Dentoxol mouthrinse dosages - Epidermolysis Bullosa, Oral Ulcer | Phase 2 | Unknown | University of Chile | 100 | 2022-04-06 | 2022-04-14 |
| A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V Afamelanotide - Xeroderma Pigmentosum | Phase 2 | Unknown | Clinuvel Europe Limited | 6 | 2022-03-28 | 2023-09-21 |
| A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP) Afamelanotide - Xeroderma Pigmentosum | Phase 2 | Unknown | Clinuvel Europe Limited | 6 | 2021-10-19 | 2023-06-18 |
| Optimizing IV Gentamicin in JEB Gentamicin Sulfate, Injectable - Junctional Epidermolysis Bullosa | Phase 1 / Phase 2 | Unknown | University of Southern California | 6 | 2019-10-31 | 2022-11-03 |
| Use of Propranolol Hydrochloride in the Treatment of Metastatic STS Propranolol Hydrochloride, Doxorubicin - Malignant Soft Tissue Sarcoma | Phase 2 | Unknown | Ain Shams University | 50 | 2019-08-30 | 2018-02-23 |
| Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Gentamicin - Recessive Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Unknown | University of Southern California | 9 | 2018-07-05 | 2022-11-03 |
| Safety Study and Preliminary Efficacy of Infusion Haploidentical Mesenchymal Stem Cells Derived From Bone Marrow for Treating Recessive Dystrophic Epidermolysis Bullosa mesenchymal stem cells derived from bone marrow (BM-MSCs) - Epidermolysis Bullosa Dystrophica, Recessive | Phase 1 / Phase 2 | Unknown | Instituto de Investigación Hospital Universitario La Paz | 9 | 2018-05-17 | 2019-11-08 |
| Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study Sirolimus 2%, Vehicle - Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner | Phase 2 | Unknown | Premier Specialists, Australia | 8 | 2016-05-01 | 2017-10-24 |
| Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa Mesenchymal stromal cells - Recessive Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Unknown | King's College London | 10 | 2015-06-01 | 2017-03-03 |
| Diacerin for the Treatment of Epidermolysis Bullosa Simplex Diacerin cream - Epidermolysis Bullosa Simplex | Phase 2 | Unknown | Tel-Aviv Sourasky Medical Center | 50 | 2015-06-01 | 2015-06-12 |
| Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita Dysport® (Botulinumtoxin A (Btx A)), Placebo - Epidermolysis Bullosa Simplex | Phase 2 | Unknown | Uppsala University | 40 | 2009-05-01 | 2011-03-09 |
Epidermolysis Bullosa Dystrophica (5) · Epidermolysis Bullosa Simplex (3) · Epidermolysis Bullosa (2) · Xeroderma Pigmentosum (2) · Epidermolysis Bullosa, Junctional (1) · Ichthyosis, X-Linked (1) · Oral Ulcer (1)
Congenital Abnormalities (13) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13) · Genetic Diseases, Inborn (13) · Skin Diseases (13) · Skin Diseases, Genetic (13) · Skin and Connective Tissue Diseases (13) · Skin Diseases, Vesiculobullous (10) · Epidermolysis Bullosa (8) · Collagen Diseases (5) · Connective Tissue Diseases (5) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · DNA Repair-Deficiency Disorders (2) · Neoplasms (2)
Gentamicins (2) · afamelanotide (2) · Doxorubicin (1) · Gels (1) · Injections (1) · Propranolol (1) · abobotulinumtoxinA (1)
Clinuvel Europe Limited (2) · University of Southern California (2) · Ain Shams University (1) · Anterogen Co., Ltd. (1) · Instituto de Investigación Hospital Universitario La Paz (1) · King's College London (1) · Phoenicis Therapeutics (1) · Premier Specialists, Australia (1) · Tel-Aviv Sourasky Medical Center (1) · University of Chile (1) · Uppsala University (1)
United States (4) · Spain (2) · Australia (1) · Belgium (1) · Chile (1) · Germany (1) · Sweden (1) · United Kingdom (1)
Carl Swartling (1) · David T. Woodley, MD (1) · Dedee F Murrell, MD (1) · Eli Sprecher, Prof. (1) · Hal Landy, MD (1) · John McGrath, FRCP/FSci/MD (1) · Mei Chen, Ph.D (1) · Mei Chen, PhD (1) · Susanne Kramer, MsC (1)